Welcome to our dedicated page for Moolec Science SEC filings (Ticker: MLEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moolec Science SA (NASDAQ: MLEC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Moolec files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, detailing material events, corporate actions, and listing-related matters for investors and analysts.
Recent Form 6-K filings referenced in public information include disclosures about Nasdaq determination letters regarding minimum bid price requirements, stockholders’ equity thresholds, and delays in filing the Form 20-F. Moolec has also used Form 6-K to report on its extraordinary general meeting of shareholders, including approval of share consolidations, and to describe appeals and hearings with Nasdaq’s Listing Qualifications Department and Hearings Panel.
Filings related to share structure changes, such as reverse stock splits and subsequent share consolidations, outline how Moolec reduced the number of issued and outstanding ordinary shares and adjusted par value per share, while stating that these actions do not affect the company’s business or operations. Other filings incorporate press releases by reference, including those announcing the closing of a strategic business combination with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC.
On Stock Titan, users can review Moolec’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents. This includes highlighting the implications of listing compliance notices, share consolidations, and other corporate actions disclosed on Form 6-K, as well as providing context for how these events relate to Moolec’s broader strategy in food-tech, life sciences, and agricultural biotechnology.
Moolec Science received a decision from a Nasdaq Hearings Panel allowing its shares to remain listed on the Nasdaq Capital Market, subject to specific conditions. The Panel found that Moolec regained compliance with the minimum bid price rule on January 16, 2026, after a reverse stock split that became effective on January 5, 2026.
The Panel noted that Moolec filed its Annual Report on Form 20-F for the year ended June 30, 2025, on December 29, 2025, and accepted the company’s plan to address the minimum stockholders’ equity requirement. Continued listing depends on Moolec providing derecognition updates by the end of February 2026, updated pro forma financial information by the end of March 2026, timely public disclosure of actions to demonstrate equity compliance by May 13, 2026, and full compliance with all Nasdaq Capital Market continued listing standards by May 13, 2026.
Moolec Science S.A. reports that Nasdaq Staff has issued a memorandum to the Nasdaq Hearings Panel supporting an exception through June 29, 2026 for the company to demonstrate compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). Nasdaq’s position is based on a material improvement in Moolec’s balance sheet after several year-end 2025 events involving certain subsidiaries.
In December 2025, bankruptcy proceedings for Bioceres S.A. and its subsidiary Bioceres LLC led to a loss of control and derecognition gains of about $91.0 million and $5.2 million, respectively. A further bankruptcy of Theo I SCSp on December 31, 2025 produced an additional derecognition gain of about $4.6 million. Together with recognizing intercompany liabilities and converting certain preference shares into ordinary shares, these changes substantially increased stockholders’ equity, and Moolec believes it has regained compliance with Nasdaq’s equity requirement while it awaits the Panel’s decision.
Moolec Science S.A. received a decision from a Nasdaq Hearings Panel granting an exception through June 29, 2026 to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The company reports that the bankruptcy of certain subsidiaries triggered loss-of-control derecognition events under IFRS, leading to estimated gains of approximately $91.0 million for Bioceres S.A., $5.2 million for Bioceres LLC, and $4.6 million for Theo I SCSp.
Together with recognition of intercompany assets and liabilities and conversion of certain preference shares into ordinary shares, these items increased Moolec’s stockholders’ equity. Based on this, Moolec believes it has regained compliance with Nasdaq’s equity standard and has notified Nasdaq, while stating it will continue taking actions to maintain ongoing listing compliance.
Moolec Science SA reported the results of a virtual extraordinary general meeting held on December 16, 2025. Shareholders representing 4,804,341 ordinary shares out of 10,891,761 entitled to vote, or 44.110% of the company’s outstanding ordinary shares, were present in person or by proxy.
Shareholders approved an ordinary resolution authorizing a share consolidation at a ratio between 1-for-10 and 1-for-25, with the exact ratio and an effective date between December 17, 2025 and May 14, 2026 to be set later by the board. After the consolidation, every 10 to 25 existing ordinary shares will be combined into 1 new ordinary share, and any fractional shares will be rounded up to the nearest whole share.
They also passed a special resolution to adopt amended and restated memorandum and articles of association immediately following the effective date, to reflect the consolidation and the rights and terms of the post-consolidation ordinary shares.
Moolec Science SA reported that Nasdaq issued a determination letter stating its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days and that it would not automatically receive the usual 180‑day grace period to regain compliance. Moolec has appealed to a Nasdaq Hearings Panel, asking for a 180‑day period to implement a compliance plan, which may include a reverse stock split if deemed in shareholders’ best interests. The appeal temporarily halts the determination letter, so the shares continue to trade on the Nasdaq Capital Market under the symbol "MLEC" while the appeal is heard on December 18, 2025. The company states that this listing issue does not affect its underlying business, operations, or SEC reporting obligations.
Moolec Science (MLEC) reported a potential contract dispute with INVIM. The company received a notice of alleged breach on October 2, 2025 related to an Assignment and Assumption Agreement tied to prior transaction instruments. INVIM asserts the Obligors failed to pay an Assignment Price of $13 million due on September 30, 2025.
Moolec disagrees, stating certain conditions precedent were never satisfied, including transfer of relevant securities and execution of a required services agreement. The company sent a formal response on October 20, 2025 rejecting the assertions and reserving all rights. Moolec intends to defend its position, noting that an adverse outcome, if INVIM ultimately prevails, could have a material adverse effect on its business, financial condition, results of operations, or liquidity.
FAQ
What is the current stock price of Moolec Science (MLEC)?
What is the market cap of Moolec Science (MLEC)?
